Pub Date : 2020-01-01DOI: 10.20517/2572-8180.2020.01
{"title":"Acknowledgement to reviewers of Journal of Unexplored Medical Data in 2019","authors":"","doi":"10.20517/2572-8180.2020.01","DOIUrl":"https://doi.org/10.20517/2572-8180.2020.01","url":null,"abstract":"","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74613772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-17DOI: 10.20517/2572-8180.2019.002
D. Lytkin, A. Zagayko, T. Briukhanova
Aim: During the study of the aromatase inhibitors effect on metabolic disorders, it was found that exemestane significantly caused ascites. This part of pre-clinical study aimed to investigate the potential dysregulatory effect of exemestan on adrenal synthesis of hormones with miniralocorticoid activity under the conditions of experimental
{"title":"Exemestane leads to hormone-associated ascites in female hamsters with experimental metabolic syndrome","authors":"D. Lytkin, A. Zagayko, T. Briukhanova","doi":"10.20517/2572-8180.2019.002","DOIUrl":"https://doi.org/10.20517/2572-8180.2019.002","url":null,"abstract":"Aim: During the study of the aromatase inhibitors effect on metabolic disorders, it was found that exemestane significantly caused ascites. This part of pre-clinical study aimed to investigate the potential dysregulatory effect of exemestan on adrenal synthesis of hormones with miniralocorticoid activity under the conditions of experimental","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"85 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84054643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-11DOI: 10.20517/2572-8180.2019.06
S. Ravera, I. Panfoli
Although the role of platelets in hemostasis and thrombotic disorders as well as their contribution to inflammation are known, recent studies support the notion that much remains to be learned about platelet bioenergetics. Recent data suggest that platelets possess extra-mitochondrial oxidative phosphorylation (OXPHOS), which could represent one of sources of the chemical energy necessary for the prompt platelets activation. However, the extra-mitochondrial OXPHOS can play both beneficial and pathological roles, since the OXPHOS is the principal responsible of oxidative stress generation. For this reason, several authors evaluated the effects of polyphenols and other antioxidants on the modulation of the platelets oxidative stress production. In conclusion, we believe that a better understanding of platelet oxidative metabolism would allow a deeper knowledge of their physiology and the designing novel treatments targeting the role of platelets in many human diseases.
{"title":"Platelet aerobic metabolism: new perspectives","authors":"S. Ravera, I. Panfoli","doi":"10.20517/2572-8180.2019.06","DOIUrl":"https://doi.org/10.20517/2572-8180.2019.06","url":null,"abstract":"Although the role of platelets in hemostasis and thrombotic disorders as well as their contribution to inflammation are known, recent studies support the notion that much remains to be learned about platelet bioenergetics. Recent data suggest that platelets possess extra-mitochondrial oxidative phosphorylation (OXPHOS), which could represent one of sources of the chemical energy necessary for the prompt platelets activation. However, the extra-mitochondrial OXPHOS can play both beneficial and pathological roles, since the OXPHOS is the principal responsible of oxidative stress generation. For this reason, several authors evaluated the effects of polyphenols and other antioxidants on the modulation of the platelets oxidative stress production. In conclusion, we believe that a better understanding of platelet oxidative metabolism would allow a deeper knowledge of their physiology and the designing novel treatments targeting the role of platelets in many human diseases.","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"187 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80008727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-21DOI: 10.20517/2572-8180.2019.01
Dillon D. McCourt, K. Parikh, A. Brady, Yue Wang, J. Kennedy, Meghan E. Buckley, Z. Ali, A. Shevade, P. Gilman, U. Wallon
{"title":"The quest for reliable prediction of chemotherapy-induced delayed nausea among breast cancer patients","authors":"Dillon D. McCourt, K. Parikh, A. Brady, Yue Wang, J. Kennedy, Meghan E. Buckley, Z. Ali, A. Shevade, P. Gilman, U. Wallon","doi":"10.20517/2572-8180.2019.01","DOIUrl":"https://doi.org/10.20517/2572-8180.2019.01","url":null,"abstract":"","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75448750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-13DOI: 10.20517/2572-8180.2019.02
K. Ayre, Catherine C. Parker
{"title":"Lymphedema after treatment of breast cancer: a comprehensive review","authors":"K. Ayre, Catherine C. Parker","doi":"10.20517/2572-8180.2019.02","DOIUrl":"https://doi.org/10.20517/2572-8180.2019.02","url":null,"abstract":"","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"282 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77973755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-15DOI: 10.20517/2572-8180.2019.05
A. Berezin, A. Berezin
There is emerging evidence that endogenous microvesicles released by platelets may play a pivotal role in pathogenesis of numerous diseases including stable and unstable ischemic heart disease, atherosclerosis, hypertension, idiopathic pulmonary hypertension, atrial fibrillation/flutter, acute and chronic heart failure, as well as systemic vasculitis, systemic lupus erythematosus, antiphospholipid syndrome, transplant rejection, diabetes-induced angiopathy. Microvesicles that leased from the platelets exist as cargo for a large of number biological-active molecules including regulatory peptides, hormones, growth factors, active molecules coordinating cell-to-cell cooperation. Moreover, platelet-derived microvesicles are concerned about a conspicuous component in regulating angiogenesis, cardiac protection, and vascular repair. Recent animal and clinical studies have shown that the number of circulating platelet-derived microvesicles may sufficiently increase in accelerating atherosclerosis, acute atherothrombotic events, i.e., recurrent ischemia, myocardial infarction, thrombosis, hypertension, and stroke, microvascular inflammation. It is suggested that exaggerating levels of circulating platelet-derived microvesicles is strongly associated with endothelial dysfunction. The review is discussed the role of platelet-derived vesicles in the pathogenesis of the cardiovascular disease, as well as diagnostic and predictive capabilities of platelet-derived vesicles as biomarkers of a natural evolution of the diseases.
{"title":"Platelet-derived vesicles: diagnostic and predictive value in cardiovascular diseases","authors":"A. Berezin, A. Berezin","doi":"10.20517/2572-8180.2019.05","DOIUrl":"https://doi.org/10.20517/2572-8180.2019.05","url":null,"abstract":"There is emerging evidence that endogenous microvesicles released by platelets may play a pivotal role in pathogenesis of numerous diseases including stable and unstable ischemic heart disease, atherosclerosis, hypertension, idiopathic pulmonary hypertension, atrial fibrillation/flutter, acute and chronic heart failure, as well as systemic vasculitis, systemic lupus erythematosus, antiphospholipid syndrome, transplant rejection, diabetes-induced angiopathy. Microvesicles that leased from the platelets exist as cargo for a large of number biological-active molecules including regulatory peptides, hormones, growth factors, active molecules coordinating cell-to-cell cooperation. Moreover, platelet-derived microvesicles are concerned about a conspicuous component in regulating angiogenesis, cardiac protection, and vascular repair. Recent animal and clinical studies have shown that the number of circulating platelet-derived microvesicles may sufficiently increase in accelerating atherosclerosis, acute atherothrombotic events, i.e., recurrent ischemia, myocardial infarction, thrombosis, hypertension, and stroke, microvascular inflammation. It is suggested that exaggerating levels of circulating platelet-derived microvesicles is strongly associated with endothelial dysfunction. The review is discussed the role of platelet-derived vesicles in the pathogenesis of the cardiovascular disease, as well as diagnostic and predictive capabilities of platelet-derived vesicles as biomarkers of a natural evolution of the diseases.","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89162278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-30DOI: 10.20517/2572-8180.2018.01
J. Heath, Melody Paulishak, C. Kasales, J. Schubart, R. Kass
Aim: To assess for factors contributing to the total delay in care, and specifically the behavioral delay-interval portion of that delay, experienced by a group of symptomatic breast cancer patients. Methods: This retrospective cohort pilot study included 24 females greater than 40 years-old with symptomatic breast cancer at time of diagnosis (including palpable mass, breast pain, other pain, discharge, nipple inversion). Participants were asked demographic information, as well as to identify, from a predefined list of options, the three most relevant causes for their delayed breast cancer diagnosis. Data sources included electronic medical record query and phone surveys. Results: Overall, 21/24 of our study’s participants identified at least one of our predetermined barriers to care as relevant to their cause for delay. The most commonly identified reasons for delay were health system utilization factors contributing to behavioral delay, including dependents/pressing matters, employment responsibilities, transportation costs and difficulty, fear of being judged by healthcare workers, and fear of not being able to afford treatment. Conclusion: Women with breast cancer can experience delays to eventual diagnosis and treatment during various timeintervals between first noticing a symptom and finally presenting to medical attention. This study provides evidence that one such possible interval is the behavioral delay interval. Health system utilization factors, psychological factors, demographic factors and help-seeking habits can contribute to an increased behavioral delay interval. Further research is warranted to address these factors and minimize their impact on patient care delivery.
{"title":"Reasons symptomatic breast cancer patients delay seeking medical care","authors":"J. Heath, Melody Paulishak, C. Kasales, J. Schubart, R. Kass","doi":"10.20517/2572-8180.2018.01","DOIUrl":"https://doi.org/10.20517/2572-8180.2018.01","url":null,"abstract":"Aim: To assess for factors contributing to the total delay in care, and specifically the behavioral delay-interval portion of that delay, experienced by a group of symptomatic breast cancer patients. Methods: This retrospective cohort pilot study included 24 females greater than 40 years-old with symptomatic breast cancer at time of diagnosis (including palpable mass, breast pain, other pain, discharge, nipple inversion). Participants were asked demographic information, as well as to identify, from a predefined list of options, the three most relevant causes for their delayed breast cancer diagnosis. Data sources included electronic medical record query and phone surveys. Results: Overall, 21/24 of our study’s participants identified at least one of our predetermined barriers to care as relevant to their cause for delay. The most commonly identified reasons for delay were health system utilization factors contributing to behavioral delay, including dependents/pressing matters, employment responsibilities, transportation costs and difficulty, fear of being judged by healthcare workers, and fear of not being able to afford treatment. Conclusion: Women with breast cancer can experience delays to eventual diagnosis and treatment during various timeintervals between first noticing a symptom and finally presenting to medical attention. This study provides evidence that one such possible interval is the behavioral delay interval. Health system utilization factors, psychological factors, demographic factors and help-seeking habits can contribute to an increased behavioral delay interval. Further research is warranted to address these factors and minimize their impact on patient care delivery.","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79097716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-27DOI: 10.20517/2572-8180.2019.07
Cosette A. Dechant, Samantha M. Thomas, L. Rosenberger, O. Fayanju, R. Greenup, E. Hwang, J. Plichta
Aim: To evaluate the association between local-regional treatment strategies on overall survival (OS), we compared elderly patients with ductal carcinoma in situ (DCIS) who underwent lumpectomy alone vs. lumpectomy + radiation or mastectomy. Methods: Patients ≥ 70 years in the National Cancer Data Base (2004-2015) with DCIS who underwent lumpectomy or mastectomy were selected. Kaplan-Meier curves were used to visualize the unadjusted OS. A Cox proportional hazards model was used to estimate the effect of local-regional treatment on OS after adjustment. Separate subgroup analyses were conducted for grade 1, estrogen receptor positive (ER+), and low-volume (< 3 cm) disease. Results: 18,451 patients met inclusion criteria (n = 13,284 lumpectomy + radiation or mastectomy; n = 5,167 lumpectomy alone). The unadjusted 10-year OS was 54% for the entire cohort. After adjustment, patients who underwent lumpectomy + radiation or mastectomy had a slightly improved OS (vs. lumpectomy alone; HR = 0.841, 95%CI: 0.774-0.914). For patients with grade 1 disease, lumpectomy + radiation or mastectomy was not associated with an improved OS (P = 0.12). For patients with ER+ disease, (lumpectomy + radiation or mastectomy) + endocrine therapy yielded the most significant improvement in OS (HR = 0.669, 95%CI: 0.598-0.748). Among patients with low-volume disease, lumpectomy + radiation or mastectomy was associated with an improved OS (HR = 0.812, 95%CI: 0.725-0.91). Conclusion: Our data suggest that chronologic age alone should not preclude a patient from receiving standard therapy for DCIS, while patient fitness, competing comorbidities, and patient preferences are critical factors to consider in light of potentially limited benefits of treatment. In favorable cancer diagnoses such as DCIS, thoughtful omission of standard therapy may be considered.
{"title":"Ductal carcinoma in situ in the elderly: what is the ideal treatment plan?","authors":"Cosette A. Dechant, Samantha M. Thomas, L. Rosenberger, O. Fayanju, R. Greenup, E. Hwang, J. Plichta","doi":"10.20517/2572-8180.2019.07","DOIUrl":"https://doi.org/10.20517/2572-8180.2019.07","url":null,"abstract":"Aim: To evaluate the association between local-regional treatment strategies on overall survival (OS), we compared elderly patients with ductal carcinoma in situ (DCIS) who underwent lumpectomy alone vs. lumpectomy + radiation or mastectomy. Methods: Patients ≥ 70 years in the National Cancer Data Base (2004-2015) with DCIS who underwent lumpectomy or mastectomy were selected. Kaplan-Meier curves were used to visualize the unadjusted OS. A Cox proportional hazards model was used to estimate the effect of local-regional treatment on OS after adjustment. Separate subgroup analyses were conducted for grade 1, estrogen receptor positive (ER+), and low-volume (< 3 cm) disease. Results: 18,451 patients met inclusion criteria (n = 13,284 lumpectomy + radiation or mastectomy; n = 5,167 lumpectomy alone). The unadjusted 10-year OS was 54% for the entire cohort. After adjustment, patients who underwent lumpectomy + radiation or mastectomy had a slightly improved OS (vs. lumpectomy alone; HR = 0.841, 95%CI: 0.774-0.914). For patients with grade 1 disease, lumpectomy + radiation or mastectomy was not associated with an improved OS (P = 0.12). For patients with ER+ disease, (lumpectomy + radiation or mastectomy) + endocrine therapy yielded the most significant improvement in OS (HR = 0.669, 95%CI: 0.598-0.748). Among patients with low-volume disease, lumpectomy + radiation or mastectomy was associated with an improved OS (HR = 0.812, 95%CI: 0.725-0.91). Conclusion: Our data suggest that chronologic age alone should not preclude a patient from receiving standard therapy for DCIS, while patient fitness, competing comorbidities, and patient preferences are critical factors to consider in light of potentially limited benefits of treatment. In favorable cancer diagnoses such as DCIS, thoughtful omission of standard therapy may be considered.","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76365631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-24DOI: 10.20517/2572-8180.2018.07
M. Papież, W. Krzyściak
Synergistic activity of parthenolide and cytarabine in acute promyelocytic leukemia Abstract Aim: Investigation of the influence of parthenolide (PTL) on cytarabine (Ara-C) action in an acute promyelocytic leukemia HL-60 cell line and the role of oxidative stress in its action. Methods: Cytotoxic effects and apoptosis were examined using propidium iodide (PI) or PI/Annexin-V staining, respectively. Cells were analyzed using flow cytometry. Results: PTL dose-dependently increased the percentage of dead cells. Cytotoxic and proapototic actions of PTL depend on the level of free radicals, because the addition of N-acetyl-L-cysteine (NAC) to incubation significantly reduced the effect of PTL. We did not observe a similar influence of NAC in the case of Ara-C activity. PTL significantly increased the cytotoxic and proapoptotic effects of Ara-C in comparison to the cytostatic drug alone. Interactions between the investigated compounds were mostly synergistic. NAC significantly reduced the cytotoxic effect of the combination of PTL plus Ara-C. Conclusion: PTL can significantly increase the cytotoxic and proapoptotic effects of Ara-C in an HL-60 cell line and this may warrant further research to improve the efficacy of acute promyelocytic leukemia therapy.
{"title":"Synergistic activity of parthenolide and cytarabine in acute promyelocytic leukemia HL-60 cell line","authors":"M. Papież, W. Krzyściak","doi":"10.20517/2572-8180.2018.07","DOIUrl":"https://doi.org/10.20517/2572-8180.2018.07","url":null,"abstract":"Synergistic activity of parthenolide and cytarabine in acute promyelocytic leukemia Abstract Aim: Investigation of the influence of parthenolide (PTL) on cytarabine (Ara-C) action in an acute promyelocytic leukemia HL-60 cell line and the role of oxidative stress in its action. Methods: Cytotoxic effects and apoptosis were examined using propidium iodide (PI) or PI/Annexin-V staining, respectively. Cells were analyzed using flow cytometry. Results: PTL dose-dependently increased the percentage of dead cells. Cytotoxic and proapototic actions of PTL depend on the level of free radicals, because the addition of N-acetyl-L-cysteine (NAC) to incubation significantly reduced the effect of PTL. We did not observe a similar influence of NAC in the case of Ara-C activity. PTL significantly increased the cytotoxic and proapoptotic effects of Ara-C in comparison to the cytostatic drug alone. Interactions between the investigated compounds were mostly synergistic. NAC significantly reduced the cytotoxic effect of the combination of PTL plus Ara-C. Conclusion: PTL can significantly increase the cytotoxic and proapoptotic effects of Ara-C in an HL-60 cell line and this may warrant further research to improve the efficacy of acute promyelocytic leukemia therapy.","PeriodicalId":17398,"journal":{"name":"Journal of Unexplored Medical Data","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75030931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：